John V. Heymach

UT MD Anderson Cancer Center

NIH Rank #4741
  • Program Leader
  • R01 Holder
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$2.1M
Fiscal year 2024
Grants Awarded
5
Active NIH grants
National Rank
#4,741
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $2.1M across 5 grants · National rank #4741.

Top grants by award amount

John V. Heymach's NIH grant portfolio, ranked by award amount.

  • 5U01CA256780-04U01
    Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
    $575.2K
    award amount
  • 5R01CA247975-05R01
    Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
    $549.2K
    award amount
  • 5R01CA234183-05R01
    Therapeutic strategies against EGFR exon 20 mutant lung cancer
    $529.6K
    award amount
  • 4P30CA016672-48P30
    Cancer Center Support Grant
    $401.1K
    award amount
  • 5P50CA070907-25P50
    Targeting Lung Cancer Vulnerabilities
    $88.8K
    award amount

Affiliations

Institutions that have administered grants for John V. Heymach.

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    UT MD Anderson Cancer Center
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #4741
  6. 2024
    Entered Top 25% Nationally
    Ranked #4741
  7. 2024
    Multi-Institutional Research
    Awards at 2 institutions